Scholarlink

<p>Neoadjuvant chemotherapy (NAC) is a widely used therapeutic strategy for patients with resectable non-small cell lung cancer (NSCLC). However, individual responses to NAC vary widely among patients, limiting its effective clinical application. In this study, we propose a weakly supervised deep learning model, DeepDrRVT, which integrates self-supervised feature extraction and attention-based deep multiple instance learning, to improve NAC decision making from pretreatment biopsy images. DeepDrRVT demonstrated superior predictive performance and generalizability, achieving AUCs of 0.954, 0.872 and 0.848 for complete pathologic response, and 0.968, 0.893 and 0.831 for major pathologic response in the training, internal validation and external validation cohorts, respectively. The DeepDrRVT digital assessment of residual viable tumor correlated significantly with the local pathologists’ visual assessment (Pearson r = 0.98, 0.80, and 0.59; digital/visual slope = 1.0, 0.8 and 0.55) and was also associated with longer disease-free survival (DFS) in all cohorts (HR = 0.455, 95% CI 0.234–0.887, <i>P</i> = 0.018; HR = 0.347, 95% CI 0.135–0.892, <i>P</i> = 0.021 and HR = 0.446, 95% CI 0.193–1.027, <i>P</i> = 0.051). Furthermore, DeepDrRVT remained an independent prognostic factor for DFS after adjustment for clinicopathologic variables (HR = 0.456, 95% CI 0.227–0.914, <i>P</i> = 0.027; HR = 0.358, 95% CI 0.135–0.949, <i>P</i> = 0.039 and HR = 0.419, 95% CI 0.181–0.974, <i>P</i> = 0.043). Thus, DeepDrRVT holds promise as an accessible and reliable tool for clinicians to make more informed treatment decisions prior to the initiation of NAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biopsy image-based deep learning for predicting pathologic response to neoadjuvant chemotherapy in patients with NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月7日

查看全文
  • Yibo Zhang,
  • Shuaibo Wang,
  • Xinying Liu,
  • Yang Qu,
  • Zijian Yang,
  • Yang Su,
  • Bin Hu,
  • Yousheng Mao,
  • Dongmei Lin,
  • Lin Yang,
  • Meng Zhou

摘要

Neoadjuvant chemotherapy (NAC) is a widely used therapeutic strategy for patients with resectable non-small cell lung cancer (NSCLC). However, individual responses to NAC vary widely among patients, limiting its effective clinical application. In this study, we propose a weakly supervised deep learning model, DeepDrRVT, which integrates self-supervised feature extraction and attention-based deep multiple instance learning, to improve NAC decision making from pretreatment biopsy images. DeepDrRVT demonstrated superior predictive performance and generalizability, achieving AUCs of 0.954, 0.872 and 0.848 for complete pathologic response, and 0.968, 0.893 and 0.831 for major pathologic response in the training, internal validation and external validation cohorts, respectively. The DeepDrRVT digital assessment of residual viable tumor correlated significantly with the local pathologists’ visual assessment (Pearson r = 0.98, 0.80, and 0.59; digital/visual slope = 1.0, 0.8 and 0.55) and was also associated with longer disease-free survival (DFS) in all cohorts (HR = 0.455, 95% CI 0.234–0.887, P = 0.018; HR = 0.347, 95% CI 0.135–0.892, P = 0.021 and HR = 0.446, 95% CI 0.193–1.027, P = 0.051). Furthermore, DeepDrRVT remained an independent prognostic factor for DFS after adjustment for clinicopathologic variables (HR = 0.456, 95% CI 0.227–0.914, P = 0.027; HR = 0.358, 95% CI 0.135–0.949, P = 0.039 and HR = 0.419, 95% CI 0.181–0.974, P = 0.043). Thus, DeepDrRVT holds promise as an accessible and reliable tool for clinicians to make more informed treatment decisions prior to the initiation of NAC.